title: Varespladib.
abstract: Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes. Varespladib acts by inhibiting secretory phospholipase A2 (sPLA2) and the drug is currently being evaluated in approximately 6500 patients with acute coronary syndromes receiving atorvastatin in the placebo-controlled VISTA 16 (NCT01130246) trial being conducted in North America and Europe. This review discusses the development history and scientific profile of this new compound.
mesh_terms: D000085:Acetates / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000378:metabolism; D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D007211:Indoles / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D007651:Keto Acids
chemical_list: D000085:Acetates; D007211:Indoles; D007651:Keto Acids; C545088:varespladib methyl